NASDAQ:ALDR Alder Biopharmaceuticals (ALDR) Stock Price, News & Analysis → AI to Meet the Same Fate as EVs? (From Porter & Company) (Ad) Free ALDR Stock Alerts Notice: This company has been marked as potentially delisted and may not be actively trading. Add Compare Share Share Today's Range$18.88▼$18.8850-Day Range$18.88▼$18.8852-Week Range$8.39▼$19.12VolumeN/AAverage Volume5.12 million shsMarket Capitalization$1.58 billionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock Analysis Get Alder Biopharmaceuticals alerts: Email Address Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. About Alder Biopharmaceuticals Stock (NASDAQ:ALDR)Alder BioPharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical company. It discovers, develops, and commercializes therapeutic antibodies to transform the treatment paradigm for patients with migraine in the United States, Australia, and Ireland. The company's lead product candidate is eptinezumab, a monoclonal antibody (mAb) inhibiting calcitonin gene-related peptide, which is in the late-stage clinical development for the prevention of migraine. It also develops ALD1910, a preclinical mAb that inhibits pituitary adenylate cyclase-activating polypeptide-38 for migraine prevention; and Clazakizumab, a mAb inhibiting the pro-inflammatory cytokine interleukin-6 that has completed two Phase 2b clinical trials. The company has strategic collaboration with CSL Limited for the development of clazakizumab as a therapeutic option for solid organ transplant rejection. Alder BioPharmaceuticals, Inc. was incorporated in 2002 and is headquartered in Bothell, Washington.Read More Ad Porter & CompanyAI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… Simply click here to read Porter’s warning on The Big AI Die-Up now. ALDR Stock News HeadlinesMarch 21, 2024 | msn.comObama Drive? Alder proposes renaming prominent Chicago street for former presidentMarch 18, 2024 | msn.comTributes paid to lifelong Swindon Town supporter Ann AlderMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… March 14, 2024 | msn.comRishi Sunak's NHS pledge one year on: Waiting lists up at Alder Hey Children's HospitalMarch 12, 2024 | msn.comMore women than men working as doctors at Alder Hey Children's Hospital – bucking trend across NHSMarch 9, 2024 | msn.comHartley, Jonathan Alder win OHSAA Division II boys basketball district championshipsFebruary 19, 2024 | msn.comSchoolboy flown to Alder Hey in serious condition after mountain fallFebruary 9, 2024 | msn.comAlder Hey Children's Trust cares for eight patients with Covid-19 in hospitalMarch 28, 2024 | Porter & Company (Ad)AI to Meet the Same Fate as EVs? When these tech bubbles burst, they invariably leave investors disillusioned by their losses. Now, many worry a similar fate is awaiting AI. And one man, legendary financial analyst Porter Stansberry, who called Nvidia at $11… February 1, 2024 | tmcnet.comNew Platform Upgrade: Cincoze Showcases the Latest Alder Lake Industrial Computer and a Wide Range of Panel PCsJanuary 31, 2024 | news.yahoo.comAlder Springs ‘Blessings Box’ offers food to those in needJanuary 15, 2024 | msn.comMultiple flu patients at Alder Hey Children's HospitalJanuary 11, 2024 | msn.comMore than four in five A&E arrivals at Alder Hey Children's Hospital seen within four hours – meeting NHS targetJanuary 3, 2024 | finance.yahoo.comDLA Piper Advises Alder Technology in Its Business Combination With Acclaim Technical ServicesDecember 20, 2023 | msn.com'Special day' - Liverpool squad spread Christmas joy with Alder Hey visitDecember 15, 2023 | msn.comFour in five A&E arrivals at Alder Hey Children's Hospital seen within four hours – meeting NHS targetDecember 14, 2023 | msn.comAlcedo's Christmas toy appeal for Alder Hey arrives in WirralDecember 14, 2023 | businesswire.comCincoze Alder Lake-based IPCs Meet the Needs of Various Industrial ApplicationsDecember 13, 2023 | msn.com'A special day for us' - 10 heart-warming pictures as Seamus Coleman joins Everton team at Alder HeyDecember 7, 2023 | msn.comCommunity clashes with Alder Hey chiefs as wait for park drags onDecember 6, 2023 | msn.comGenerous schoolgirl marks five years donating Christmas presents to Alder HeyDecember 1, 2023 | msn.comA third of staff absences in Alder Hey Children's Hospital are stress-relatedNovember 29, 2023 | msn.comWirral mum turns house into ‘Christmas wonderland’ in aid of Alder HeyNovember 20, 2023 | msn.comState of the art cinema coming to Alder Hey Children’s HospitalNovember 17, 2023 | msn.com19 photos capture life at the old Alder Hey Children's HospitalNovember 15, 2023 | msn.comState of the art cinema to give Alder Hey patients 'magical experience'October 24, 2023 | msn.comMadison Alder Vidaver announces run for Dane Co. Executive seatSee More Headlines Receive ALDR Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Alder Biopharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/07/2018Today3/28/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical Preparations Sub-IndustryN/A Current SymbolNASDAQ:ALDR CUSIPN/A CIK1423824 Webwww.alderbio.com Phone425-205-2900FaxN/AEmployees202Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($4.87) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-296,430,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-226.13% Return on Assets-66.86% Debt Debt-to-Equity Ratio1.74 Current Ratio8.94 Quick Ratio8.94 Sales & Book Value Annual Sales$1.62 million Price / Sales977.10 Cash FlowN/A Price / Cash FlowN/A Book Value$1.61 per share Price / Book11.73Miscellaneous Outstanding Shares83,840,000Free FloatN/AMarket Cap$1.58 billion OptionableOptionable Beta2.64 13 Stocks Institutional Investors Won't Stop BuyingWhich stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.Get This Free Report Key ExecutivesDr. John A. Latham (Age 59)Co-Founder & Chief Scientific Officer Mr. Larry K. Benedict (Age 58)Principal Accounting Officer & Exec. VP Dr. Jeffrey T. L. Smith (Age 59)Managing Director of Alder Biopharmaceuticals Limited Mr. Robert W. Azelby (Age 51)Pres, CEO & Director Mr. Carlos CampoyChief Financial OfficerKey CompetitorsTaro Pharmaceutical IndustriesNYSE:TAROZai LabNASDAQ:ZLABEdgewise TherapeuticsNASDAQ:EWTXDynavax TechnologiesNASDAQ:DVAXMorphicNASDAQ:MORFView All Competitors ALDR Stock Analysis - Frequently Asked Questions How were Alder Biopharmaceuticals' earnings last quarter? Alder Biopharmaceuticals Inc (NASDAQ:ALDR) released its quarterly earnings data on Tuesday, August, 7th. The biopharmaceutical company reported ($1.04) EPS for the quarter, topping the consensus estimate of ($1.05) by $0.01. What other stocks do shareholders of Alder Biopharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Alder Biopharmaceuticals investors own include NVIDIA (NVDA), AbbVie (ABBV), (CPXX) (CPXX), Micron Technology (MU), Gilead Sciences (GILD), Alibaba Group (BABA), Synergy Pharmaceuticals (SGYP), Sarepta Therapeutics (SRPT) and Celldex Therapeutics (CLDX). This page (NASDAQ:ALDR) was last updated on 3/28/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeGrab Your Free Bitcoin Today!Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders AllianceForget AI, Imperium Is Expected to Grow 320,00% in 3 YearsBanyan Hill PublishingFed launches fourth dollar overhaulStansberry ResearchForget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THISParadigm PressThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading Academy Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Alder Biopharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.